Sourcing Exosomes in Ohio
Licensed Ohio practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Ohio buyers need their own professional license and NPI; the wholesale distributor license is the supplier’s obligation, not the purchaser’s.
Ohio is unusual in licensing both ends of a drug sale. The Board of Pharmacy licenses the shipping distributor, and separately runs a Terminal Distributor of Dangerous Drugs framework for possession at the practice level, with exemptions that turn on who owns the practice. That second layer is worth understanding before structuring an Ohio practice.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Ohio? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Ohio
ExaVeyra ships to licensed practices in all 50 states, Ohio included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Ohio professional license in good standing, verifiable through the eLicense Ohio portal at elicense.ohio.gov.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- An Ohio sales and use tax resale certificate through the Ohio Department of Taxation if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Ohio licenses wholesale distributors, manufacturers, outsourcing facilities, third-party logistics providers, and repackagers of dangerous drugs through the State Board of Pharmacy, whether located within or outside the state, with a dedicated nonresident category for out-of-state distributors. The distinctive feature is the second layer: Ohio also licenses possession at the receiving end through the Terminal Distributor of Dangerous Drugs framework under ORC 4729.54. The exemptions in ORC 4729.541 cover an individual licensed prescriber and business entities wholly owned by licensed prescribers, and fall away for pain management clinics and for possession of controlled substances or compounded drugs. Whether a particular product counts as a dangerous drug, and whether a particular practice structure sits inside the exemptions, are classification questions for the Board and counsel. The wholesale license itself sits with the distributor, not with the purchasing practice.
Ohio Rev. Code 4729.52 to 4729.54; Ohio Rev. Code 4729.541 · State of Ohio Board of Pharmacy
Ohio regenerative-medicine law
Ohio has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Ohio has enacted no statute addressing unapproved regenerative therapy: no authorization law of the Florida, Texas, or Georgia kind, no disclosure law of the California kind, and no documentation statute of the Tennessee kind. Practice in this area is governed by the Medical Practice Act in ORC Chapter 4731, the Nurse Practice Act in ORC Chapter 4723, the dangerous drug framework in ORC Chapter 4729, and the boards that administer them, alongside federal law, which is the only layer that addresses the products themselves.
How this applies to exosomes
Ohio has no stem cell statute, so there is no Ohio definition to read exosomes into or out of. What Ohio does have is a dangerous drug framework administered by the Board of Pharmacy, and whether any given product falls within it is a classification question that the framework itself does not answer for unapproved biologics. Exosomes are acellular extracellular vesicles, and they are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Ohio practice
Ohio is a collaboration state for nurse practitioners, not an independent practice state, so every APRN-led service traces to a standard care arrangement with a physician in the same or a similar specialty. The practical planning point is OAC 4731-23: a physician who delegates drug administration to an unlicensed person generally must be on site, and anesthesia and intravenous drugs cannot be delegated to unlicensed persons, which shapes staffing in aesthetic practices more than any other single rule.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the State Medical Board of Ohio perform medical acts within their scope and are the source of any delegation. Delegation of medical tasks to unlicensed persons is governed by OAC Chapter 4731-23, which requires the physician to determine the delegate’s competence and the task’s suitability before delegating, and which prohibits delegating certain tasks outright. |
| NP / APRN | Ohio certified nurse practitioners practice under a written standard care arrangement with a collaborating physician under ORC 4723.431. The collaborating physician must practice in the same or a similar specialty, and the arrangement covers referral criteria, consultation, coverage, dispute resolution, and quality assurance. The Board of Nursing does not pre-approve the arrangement but may review it, and the APRN files the collaborating physician’s details with the Board within 30 days of starting. |
| PA | Physician assistants practice under a supervision agreement entered with a supervising physician before practice begins, required by ORC 4730.19, within the scope the supervising physician delegates. |
| RN | Registered nurses administer treatments on the order of an authorized prescriber within the Nurse Practice Act, ORC Chapter 4723. Where a physician instead delegates drug administration to an unlicensed person under OAC 4731-23, on-site supervision is generally required, and anesthesia and intravenous drug administration cannot be delegated to unlicensed persons at all. |
Good faith examination
Ohio expects a prescriber evaluation before delegated treatment: the standard care arrangement defines when the APRN evaluates and refers, and OAC 4731-23 requires the delegating physician to have determined that the task is appropriate for the specific patient before delegating it. Confirm current expectations with the State Medical Board of Ohio and the Ohio Board of Nursing, since the detail sits in board rules rather than a single statute.
Ownership and clinic licensing
Ohio recognizes the corporate practice of medicine doctrine through its Medical Practice Act and licensure case law rather than through a single bright-line statute, and professional entities with management services arrangements are the usual structures. Ownership matters twice in Ohio: once for the corporate practice question, and again because the Terminal Distributor of Dangerous Drugs exemptions in ORC 4729.541 attach to prescriber-owned entities and can fall away when ownership moves to non-prescribers. Structure the entity with Ohio counsel before opening.
Cold chain into Ohio
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Ohio order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Columbus | Franklin | Largest Ohio market, with a broad aesthetic and dermatology base. |
| Cleveland | Cuyahoga | Major clinical and academic medical presence on the north coast. |
| Cincinnati | Hamilton | Southwest Ohio market serving the Kentucky and Indiana borders. |
| Dayton | Montgomery | Miami Valley market with a growing med spa segment. |
| Akron | Summit | Served alongside Cleveland, with sports medicine demand. |
| Toledo | Lucas | Northwest Ohio hub on the Michigan border. |
- Ohio orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Wholesale exosome supply by city in Ohio
Each city page covers local receiving conditions, delivery disruptions and business license rules for Ohio practices in that area.
Practice types we supply in Ohio
Ohio licensing and verification
State Medical Board of Ohio
Administers the delegation rules in OAC Chapter 4731-23.
Ohio Board of Nursing
Receives APRN collaborating physician filings and may review standard care arrangements.
State of Ohio Board of Pharmacy
Licenses wholesale distributors and administers the terminal distributor framework.
Ohio Department of Taxation
Sales and use tax registration and resale certificates.
Ohio sourcing questions
- Does Ohio have a stem cell law?
- No. Ohio has enacted no stem cell authorization law, disclosure law, or documentation statute, so there is no Ohio definition that reaches stem cells or exosomes either way. Practice is governed by the Medical Practice Act, the Nurse Practice Act, and the dangerous drug framework in ORC Chapter 4729, and the products themselves are governed by federal law.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- Does my Ohio clinic need a wholesale distributor license to buy exosomes?
- No. The Wholesale Distributor of Dangerous Drugs license under ORC 4729.52 is held by the distributor shipping into Ohio, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- What is a Terminal Distributor of Dangerous Drugs license, and does my practice need one?
- It is Ohio’s license for possessing dangerous drugs at the practice level, under ORC 4729.54. The exemptions in ORC 4729.541 cover individual licensed prescribers and entities wholly owned by licensed prescribers, and they fall away for pain management clinics and for possession of controlled substances or compounded drugs. Whether a specific practice structure needs a TDDD, and how any specific product is classified, are questions for the Board of Pharmacy and Ohio counsel, not something a supplier can answer for you.
- What does an Ohio nurse practitioner need in place?
- A written standard care arrangement with a collaborating physician under ORC 4723.431. The collaborating physician must practice in the same or a similar specialty, the arrangement covers referral, consultation, coverage, dispute resolution, and quality assurance, and the APRN files the collaborating physician’s details with the Board of Nursing within 30 days of beginning practice. Ohio is a collaboration state, not an independent practice state.
- Can a registered nurse inject in Ohio?
- Registered nurses administer treatments on the order of an authorized prescriber within the Nurse Practice Act. The sharper Ohio limits apply to unlicensed persons: under OAC 4731-23 a physician who delegates drug administration to an unlicensed person generally must be on site, and anesthesia and intravenous drug administration cannot be delegated to unlicensed persons at all.
- How long does cold-chain shipping take to Ohio?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- ORC 4729.52, wholesale distributor and other drug distributor licensure (accessed 16 October 2026)
- ORC 4729.54, terminal distributor of dangerous drugs licensure (accessed 16 October 2026)
- ORC 4729.541, terminal distributor licensure exemptions (accessed 16 October 2026)
- State of Ohio Board of Pharmacy, drug distributor licensing (accessed 16 October 2026)
- State of Ohio Board of Pharmacy, terminal distributor licensing (accessed 16 October 2026)
- ORC 4723.431, APRN standard care arrangements (accessed 16 October 2026)
- Ohio Department of Taxation (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current field standard for characterizing extracellular vesicle preparations, which is the benchmark behind the particle characterization data on a Kimera Certificate of Analysis.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: Defines what a mesenchymal stromal cell derived small EV preparation must demonstrate, supporting this page’s description of perinatal MSC-derived exosome source material and its documentation.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing and safety expectations for EV-based products in trials, which is the context for this page’s statement that no exosome product is FDA approved.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.